Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors

Tomoko Iwata-Kajihara, Hidetoshi Sumimoto, Naoshi Kawamura, Ryo Ueda, Tomomi Takahashi, Hiroyuki Mizuguchi, Makoto Miyagishi, Kiyoshi Takeda, Yutaka Kawakami

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

STAT3 signaling constitutes an important negative feedback mechanism for the maintenance of immune homeostasis, a suppressive signal for the Th1 immune response in murine macrophages, and a cancer immune evasion signal in various immune cells. The strategy for STAT3 signal inhibition should be considered, because these features could impede effective cancer immunotherapy. We have evaluated the effects of STAT3 inactivation in dendritic cells (DCs) on immune responses in mice and humans. DCs derived from LysMcre/STAT3flox/flox mice displayed higher cytokine production in response to TLR stimulation, activated T cells more efficiently, and were more resistant to the suppression of cytokine production by cancer-derived immunosuppressive factors compared with DCs from control littermates. Antitumor activities of STAT3-depleted and control DCs were compared by intratumoral administration of gp70 Ag peptide-pulsed DCs in the therapeutic MC38 tumor model. Intratumoral administration of STAT3-depleted DCs significantly inhibited MC38 tumor growth of both injected and nontreated remote tumors. The inhibition was accompanied by an increase in gp70-specific T cell response as well as in systemic Th1 immune response. STAT3-depleted human DCs with adenoviral STAT3 short hairpin RNAwere also capable of producing more cytokines with TLR stimulation and more resistant to cancer-derived factors, and they induced tumor Ag-specific T cells more efficiently than control DCs. The identified role of DC STAT3 signaling in both in vivo therapeutic tumor models in mice and in vitro-specific T cell induction in humans indicates that STAT3-inactivated DCs may be a promising approach for cancer immunotherapy.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalJournal of Immunology
Volume187
Issue number1
DOIs
Publication statusPublished - 2011 Jul 1

Fingerprint

Immunotherapy
Dendritic Cells
Neoplasms
T-Lymphocytes
Cytokines
Immune Evasion
Immunosuppressive Agents
Homeostasis
Macrophages
Maintenance
Peptides
Therapeutics
Growth

ASJC Scopus subject areas

  • Immunology

Cite this

Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. / Iwata-Kajihara, Tomoko; Sumimoto, Hidetoshi; Kawamura, Naoshi; Ueda, Ryo; Takahashi, Tomomi; Mizuguchi, Hiroyuki; Miyagishi, Makoto; Takeda, Kiyoshi; Kawakami, Yutaka.

In: Journal of Immunology, Vol. 187, No. 1, 01.07.2011, p. 27-36.

Research output: Contribution to journalArticle

Iwata-Kajihara, T, Sumimoto, H, Kawamura, N, Ueda, R, Takahashi, T, Mizuguchi, H, Miyagishi, M, Takeda, K & Kawakami, Y 2011, 'Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors', Journal of Immunology, vol. 187, no. 1, pp. 27-36. https://doi.org/10.4049/jimmunol.1002067
Iwata-Kajihara, Tomoko ; Sumimoto, Hidetoshi ; Kawamura, Naoshi ; Ueda, Ryo ; Takahashi, Tomomi ; Mizuguchi, Hiroyuki ; Miyagishi, Makoto ; Takeda, Kiyoshi ; Kawakami, Yutaka. / Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. In: Journal of Immunology. 2011 ; Vol. 187, No. 1. pp. 27-36.
@article{c1d867f33d9c47b9be7b55682f2d6fbf,
title = "Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors",
abstract = "STAT3 signaling constitutes an important negative feedback mechanism for the maintenance of immune homeostasis, a suppressive signal for the Th1 immune response in murine macrophages, and a cancer immune evasion signal in various immune cells. The strategy for STAT3 signal inhibition should be considered, because these features could impede effective cancer immunotherapy. We have evaluated the effects of STAT3 inactivation in dendritic cells (DCs) on immune responses in mice and humans. DCs derived from LysMcre/STAT3flox/flox mice displayed higher cytokine production in response to TLR stimulation, activated T cells more efficiently, and were more resistant to the suppression of cytokine production by cancer-derived immunosuppressive factors compared with DCs from control littermates. Antitumor activities of STAT3-depleted and control DCs were compared by intratumoral administration of gp70 Ag peptide-pulsed DCs in the therapeutic MC38 tumor model. Intratumoral administration of STAT3-depleted DCs significantly inhibited MC38 tumor growth of both injected and nontreated remote tumors. The inhibition was accompanied by an increase in gp70-specific T cell response as well as in systemic Th1 immune response. STAT3-depleted human DCs with adenoviral STAT3 short hairpin RNAwere also capable of producing more cytokines with TLR stimulation and more resistant to cancer-derived factors, and they induced tumor Ag-specific T cells more efficiently than control DCs. The identified role of DC STAT3 signaling in both in vivo therapeutic tumor models in mice and in vitro-specific T cell induction in humans indicates that STAT3-inactivated DCs may be a promising approach for cancer immunotherapy.",
author = "Tomoko Iwata-Kajihara and Hidetoshi Sumimoto and Naoshi Kawamura and Ryo Ueda and Tomomi Takahashi and Hiroyuki Mizuguchi and Makoto Miyagishi and Kiyoshi Takeda and Yutaka Kawakami",
year = "2011",
month = "7",
day = "1",
doi = "10.4049/jimmunol.1002067",
language = "English",
volume = "187",
pages = "27--36",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors

AU - Iwata-Kajihara, Tomoko

AU - Sumimoto, Hidetoshi

AU - Kawamura, Naoshi

AU - Ueda, Ryo

AU - Takahashi, Tomomi

AU - Mizuguchi, Hiroyuki

AU - Miyagishi, Makoto

AU - Takeda, Kiyoshi

AU - Kawakami, Yutaka

PY - 2011/7/1

Y1 - 2011/7/1

N2 - STAT3 signaling constitutes an important negative feedback mechanism for the maintenance of immune homeostasis, a suppressive signal for the Th1 immune response in murine macrophages, and a cancer immune evasion signal in various immune cells. The strategy for STAT3 signal inhibition should be considered, because these features could impede effective cancer immunotherapy. We have evaluated the effects of STAT3 inactivation in dendritic cells (DCs) on immune responses in mice and humans. DCs derived from LysMcre/STAT3flox/flox mice displayed higher cytokine production in response to TLR stimulation, activated T cells more efficiently, and were more resistant to the suppression of cytokine production by cancer-derived immunosuppressive factors compared with DCs from control littermates. Antitumor activities of STAT3-depleted and control DCs were compared by intratumoral administration of gp70 Ag peptide-pulsed DCs in the therapeutic MC38 tumor model. Intratumoral administration of STAT3-depleted DCs significantly inhibited MC38 tumor growth of both injected and nontreated remote tumors. The inhibition was accompanied by an increase in gp70-specific T cell response as well as in systemic Th1 immune response. STAT3-depleted human DCs with adenoviral STAT3 short hairpin RNAwere also capable of producing more cytokines with TLR stimulation and more resistant to cancer-derived factors, and they induced tumor Ag-specific T cells more efficiently than control DCs. The identified role of DC STAT3 signaling in both in vivo therapeutic tumor models in mice and in vitro-specific T cell induction in humans indicates that STAT3-inactivated DCs may be a promising approach for cancer immunotherapy.

AB - STAT3 signaling constitutes an important negative feedback mechanism for the maintenance of immune homeostasis, a suppressive signal for the Th1 immune response in murine macrophages, and a cancer immune evasion signal in various immune cells. The strategy for STAT3 signal inhibition should be considered, because these features could impede effective cancer immunotherapy. We have evaluated the effects of STAT3 inactivation in dendritic cells (DCs) on immune responses in mice and humans. DCs derived from LysMcre/STAT3flox/flox mice displayed higher cytokine production in response to TLR stimulation, activated T cells more efficiently, and were more resistant to the suppression of cytokine production by cancer-derived immunosuppressive factors compared with DCs from control littermates. Antitumor activities of STAT3-depleted and control DCs were compared by intratumoral administration of gp70 Ag peptide-pulsed DCs in the therapeutic MC38 tumor model. Intratumoral administration of STAT3-depleted DCs significantly inhibited MC38 tumor growth of both injected and nontreated remote tumors. The inhibition was accompanied by an increase in gp70-specific T cell response as well as in systemic Th1 immune response. STAT3-depleted human DCs with adenoviral STAT3 short hairpin RNAwere also capable of producing more cytokines with TLR stimulation and more resistant to cancer-derived factors, and they induced tumor Ag-specific T cells more efficiently than control DCs. The identified role of DC STAT3 signaling in both in vivo therapeutic tumor models in mice and in vitro-specific T cell induction in humans indicates that STAT3-inactivated DCs may be a promising approach for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79960409792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960409792&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1002067

DO - 10.4049/jimmunol.1002067

M3 - Article

VL - 187

SP - 27

EP - 36

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -